BACKGROUND: The purpose of this analysis is to report long-term health-related quality of life (HRQoL) among brain tumor survivors treated with proton therapy (PRT) at a very young age. METHODS: Fifty-nine children <4 years old received PRT between 2000 and 2011. Forty families participated. HRQoL was assessed by child self-report (CSR; age ≥5) and parent proxy report (PPR; age 2+) using the PedsQL Core. RESULTS: The median age was 2.5 years (range, 0.3-3.8) at PRT and 9.1 years (5.5-18) at last follow-up. The most common diagnoses were ependymoma (n = 22) and medulloblastoma (n = 7). Median follow-up is 6.7 years (3-15.4). Follow-up mean CSR and PPR scores were: total core (78.4 and 72.9), physical (82.9 and 75.2), psychosocial (76.0 and 71.6), emotional (74.4 and 70.7), social (81.2 and 75.1), and school (72.4 and 69.9). Parent-reported HRQoL fell within a previously defined range for healthy children in 37.5% of patients, and for children with severe health conditions in 45% of patients. PPR HRQoL was stable from baseline to last follow-up among all domains except for social functioning. History of gastrostomy tube was significantly associated with poorer CSR and PPR HRQoL on multivariable analysis. Ninety percent of children functioned in a regular classroom, 14 (36%) used a classroom aid, 9 (23%) used an outside tutor, and 18 (46%) had an individualized education plan. CONCLUSION: Long-term HRQoL among brain tumor survivors treated with PRT at a very young age is variable, with over a third achieving HRQoL levels commensurate with healthy children. KEY POINTS: 1. One third of survivors reported long-term HRQoL scores comparable to those of healthy children.2. Treatment for hydrocephalus or a feeding tube was associated with significantly lower HRQoL.3. Total core HRQoL scores remained stable from baseline to last follow-up.
BACKGROUND: The purpose of this analysis is to report long-term health-related quality of life (HRQoL) among brain tumor survivors treated with proton therapy (PRT) at a very young age. METHODS: Fifty-nine children <4 years old received PRT between 2000 and 2011. Forty families participated. HRQoL was assessed by child self-report (CSR; age ≥5) and parent proxy report (PPR; age 2+) using the PedsQL Core. RESULTS: The median age was 2.5 years (range, 0.3-3.8) at PRT and 9.1 years (5.5-18) at last follow-up. The most common diagnoses were ependymoma (n = 22) and medulloblastoma (n = 7). Median follow-up is 6.7 years (3-15.4). Follow-up mean CSR and PPR scores were: total core (78.4 and 72.9), physical (82.9 and 75.2), psychosocial (76.0 and 71.6), emotional (74.4 and 70.7), social (81.2 and 75.1), and school (72.4 and 69.9). Parent-reported HRQoL fell within a previously defined range for healthy children in 37.5% of patients, and for children with severe health conditions in 45% of patients. PPR HRQoL was stable from baseline to last follow-up among all domains except for social functioning. History of gastrostomy tube was significantly associated with poorer CSR and PPR HRQoL on multivariable analysis. Ninety percent of children functioned in a regular classroom, 14 (36%) used a classroom aid, 9 (23%) used an outside tutor, and 18 (46%) had an individualized education plan. CONCLUSION: Long-term HRQoL among brain tumor survivors treated with PRT at a very young age is variable, with over a third achieving HRQoL levels commensurate with healthy children. KEY POINTS: 1. One third of survivors reported long-term HRQoL scores comparable to those of healthy children.2. Treatment for hydrocephalus or a feeding tube was associated with significantly lower HRQoL.3. Total core HRQoL scores remained stable from baseline to last follow-up.
Authors: Thomas E Merchant; Erin N Kiehna; Chenghong Li; Xiaoping Xiong; Raymond K Mulhern Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-22 Impact factor: 7.038
Authors: Margaret B Pulsifer; Roshan V Sethi; Karen A Kuhlthau; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2015-06-14 Impact factor: 7.038
Authors: I-Chan Huang; Lindsay A Thompson; Yueh-Yun Chi; Caprice A Knapp; Dennis A Revicki; Michael Seid; Elizabeth A Shenkman Journal: Value Health Date: 2009 Jul-Aug Impact factor: 5.725
Authors: Marcos Di Pinto; Heather M Conklin; Chenghong Li; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-04 Impact factor: 7.038
Authors: Torunn I Yock; Sundeep Bhat; Jackie Szymonifka; Beow Y Yeap; Jennifer Delahaye; Sarah S Donaldson; Shannon M MacDonald; Margaret B Pulsifer; Kristen S Hill; Thomas F DeLaney; David Ebb; Mary Huang; Nancy J Tarbell; Paul Graham Fisher; Karen A Kuhlthau Journal: Radiother Oncol Date: 2014-10-07 Impact factor: 6.280
Authors: Sarah Metzger; Annette Weiser; Nicolas U Gerber; Maria Otth; Katrin Scheinemann; Niklaus Krayenbühl; Michael A Grotzer; Ana S Guerreiro Stucklin Journal: J Neurooncol Date: 2022-02-11 Impact factor: 4.506
Authors: Nicholas Major; Neal A Patel; Josiah Bennett; Ena Novakovic; Dana Poloni; Mickey Abraham; Nolan J Brown; Julian L Gendreau; Ronald Sahyouni; Joshua Loya Journal: J Pers Med Date: 2022-06-27
Authors: Mikaela Doig; Eva Bezak; Nayana Parange; Peter Gorayski; Victoria Bedford; Michala Short Journal: Cancers (Basel) Date: 2022-08-15 Impact factor: 6.575